← Illumina overview

Illumina vs IQVIA: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Illumina Inc (ILMN)

Q3 2026
▲2▼1

Illumina Surges on Earnings Beat, S&P 500 Entry, Biotech Boom

  • Earnings Beat and Raised Guidance Illumina beat earnings and raised guidance, with revenue up 4.8% to $1.09 billion. Clinical sequencing demand stayed strong, growing 20% outside China, and NovaSeq X placements topped 80 units.

    This point explains the fundamental business strength that drove the stock higher.

  • S&P 500 Inclusion and Biotech Boom The stock gained 46% amid a biotech boom, and Illumina joined the S&P 500, attracting index-fund demand. Eli Lilly joined its Billion Cell Atlas, and Merck/Moderna's cancer vaccine success boosted shares 15.6%.

    This point captures the market and partnership catalysts that amplified the stock's rise.

  • Roche Launches Cheaper Competing Sequencer Roche launched a competing sequencer at $750,000, well below Illumina's $985,000–$1.25 million, threatening its ~70% market share and potentially forcing price cuts or slower sales. Analysts expect gradual share erosion rather than collapse.

    This point highlights the main competitive threat that could pressure future growth.

August 2026
▲4

Illumina lifts outlook, joins S&P 500, and gains AI drug-discovery partners

  • Raised 2026 revenue guidance on clinical sequencing demand Illumina lifted its full-year 2026 revenue outlook to $4.60–$4.64 billion, up from the prior range, as clinical sequencing and consumables demand ran stronger than expected. That tells investors the core business is growing faster than previously thought, which supports a higher stock price.

    This is the single biggest new fundamental driver of the period, directly raising the company's own sales forecast.

  • Eli Lilly joins Illumina's Billion Cell Atlas Eli Lilly became a founding member of Illumina's Billion Cell Atlas, a huge map of how genes behave in disease. Lilly and other drugmakers pay to use Illumina's sequencing and data, so more partners mean more recurring demand for Illumina's machines and services.

    It is a new commercial partnership that expands demand for Illumina's platform and validates its data strategy.

  • Cancer vaccine success boosts demand for Illumina sequencers Merck and Moderna's positive Phase 3 cancer vaccine results lifted Illumina shares 15.6% because every personalized cancer vaccine dose requires Illumina's NovaSeq X sequencers. If this new class of treatments wins approval, it creates a large, recurring need for Illumina's machines and consumables.

    It shows a new end-market — personalized cancer vaccines — that could become a major source of future demand for Illumina.

  • Illumina to join the S&P 500 index Illumina will move from the S&P 400 into the S&P 500 on September 21. Index funds that track the S&P 500 must buy the stock, creating automatic demand. It also raises Illumina's profile among large investors, which can support the share price over time.

    It is a new capital-markets event that mechanically increases demand for ILMN shares.

Latest
▲4

Illumina lifts outlook, joins S&P 500, and gains AI drug-discovery partners

  • Raised 2026 revenue guidance on clinical sequencing demand Illumina lifted its full-year 2026 revenue outlook to $4.60–$4.64 billion, up from the prior range, as clinical sequencing and consumables demand ran stronger than expected. That tells investors the core business is growing faster than previously thought, which supports a higher stock price.

    This is the single biggest new fundamental driver of the period, directly raising the company's own sales forecast.

  • Eli Lilly joins Illumina's Billion Cell Atlas Eli Lilly became a founding member of Illumina's Billion Cell Atlas, a huge map of how genes behave in disease. Lilly and other drugmakers pay to use Illumina's sequencing and data, so more partners mean more recurring demand for Illumina's machines and services.

    It is a new commercial partnership that expands demand for Illumina's platform and validates its data strategy.

  • Cancer vaccine success boosts demand for Illumina sequencers Merck and Moderna's positive Phase 3 cancer vaccine results lifted Illumina shares 15.6% because every personalized cancer vaccine dose requires Illumina's NovaSeq X sequencers. If this new class of treatments wins approval, it creates a large, recurring need for Illumina's machines and consumables.

    It shows a new end-market — personalized cancer vaccines — that could become a major source of future demand for Illumina.

  • Illumina to join the S&P 500 index Illumina will move from the S&P 400 into the S&P 500 on September 21. Index funds that track the S&P 500 must buy the stock, creating automatic demand. It also raises Illumina's profile among large investors, which can support the share price over time.

    It is a new capital-markets event that mechanically increases demand for ILMN shares.

July 2026
▲3▼1

Illumina beats earnings, raises guidance, but Roche undercuts with cheaper sequencer

  • Earnings beat and raised guidance Illumina reported quarterly revenue of $1.09 billion, up 4.8% from a year ago, and raised its full-year profit guidance above what analysts expected. This shows the company is growing and more profitable than thought, which pushes the stock up because investors pay more for a business that earns more.

    This is the biggest new positive event this period and directly explains the stock's jump.

  • Roche launches cheaper competing sequencer Roche launched a gene sequencing machine priced at $750,000, well below Illumina's NovaSeq X at $985,000 to $1.25 million. This threatens Illumina's roughly 70% market share and could force price cuts or slow sales, weighing on the stock. Analysts expect a gradual share shift, not a sudden collapse.

    This is a new competitive threat that directly pressures Illumina's pricing and market dominance.

  • Clinical sequencing demand stays strong Clinical sequencing consumables demand outside China rose 20% for the second straight quarter, and NovaSeq X placements topped 80 units. Clinical tests now make up over 60% of sequencing consumables, giving Illumina recurring revenue and better long-term earnings visibility, which supports a higher stock price.

    This shows the underlying demand driving Illumina's growth is durable, a key reason the stock has surged.

  • Biotech sector boom lifts Illumina The biotech sector is hitting new highs as the AI trade cools, and Illumina has gained about 46% this year. A stronger drug development cycle and renewed investor interest in biotech pull money into the sector, lifting Illumina's stock along with it. This is a broad tailwind, not company-specific.

    This explains the sector-wide force behind Illumina's rally, giving the big-picture context.

▲3▼1

Illumina beats earnings, raises guidance, but Roche undercuts with cheaper sequencer

  • Earnings beat and raised guidance Illumina reported quarterly revenue of $1.09 billion, up 4.8% from a year ago, and raised its full-year profit guidance above what analysts expected. This shows the company is growing and more profitable than thought, which pushes the stock up because investors pay more for a business that earns more.

    This is the biggest new positive event this period and directly explains the stock's jump.

  • Roche launches cheaper competing sequencer Roche launched a gene sequencing machine priced at $750,000, well below Illumina's NovaSeq X at $985,000 to $1.25 million. This threatens Illumina's roughly 70% market share and could force price cuts or slow sales, weighing on the stock. Analysts expect a gradual share shift, not a sudden collapse.

    This is a new competitive threat that directly pressures Illumina's pricing and market dominance.

  • Clinical sequencing demand stays strong Clinical sequencing consumables demand outside China rose 20% for the second straight quarter, and NovaSeq X placements topped 80 units. Clinical tests now make up over 60% of sequencing consumables, giving Illumina recurring revenue and better long-term earnings visibility, which supports a higher stock price.

    This shows the underlying demand driving Illumina's growth is durable, a key reason the stock has surged.

  • Biotech sector boom lifts Illumina The biotech sector is hitting new highs as the AI trade cools, and Illumina has gained about 46% this year. A stronger drug development cycle and renewed investor interest in biotech pull money into the sector, lifting Illumina's stock along with it. This is a broad tailwind, not company-specific.

    This explains the sector-wide force behind Illumina's rally, giving the big-picture context.

IQVIA Holdings Inc (IQV)

Q3 2026
▲3▼1

IQVIA Surges on Strong Q2, AI Push, and Buybacks

  • Q2 Beat and Guidance Raise IQVIA beat Q2 2026 estimates with revenue up 8.7% and EPS of $3.15, raised full-year guidance, and posted record bookings of $3.15B (up 19%) plus a $34.2B backlog. Shares jumped.

    This is the primary new event that drove the stock higher during the period.

  • AI Platforms and Gene Therapy Partnership New AI platforms aim to cut trial delays by up to two years, and a Medera partnership expands gene therapy reach. These initiatives position IQVIA for future growth and efficiency.

    These new strategic moves support the bullish narrative and future earnings potential.

  • Buybacks and Attractive Valuation The company executed $950M in buybacks, and the stock remains cheap at 16.2x forward earnings. Shares have rallied 42% in three months, aided by these repurchases.

    Buybacks and low valuation attracted investors and contributed to the price rally.

  • Debt Refinancing Raises Interest Costs IQVIA priced $2B in 6.375% senior notes to refinance 5% debt, adding roughly $27.5M in annual interest expense—a modest but real headwind to future profits. Also, the rally means shares are no longer inexpensive.

    This is a counterweight that could pressure future earnings and limit further upside.

August 2026
▲3▼1

IQVIA Surges on Strong Q2, AI Push, and Buybacks

  • Q2 Beat and Guidance Raise IQVIA beat Q2 2026 estimates with revenue up 8.7% and EPS of $3.15, raised full-year guidance, and posted record bookings of $3.15B (up 19%) plus a $34.2B backlog. Shares jumped.

    This is the primary new event that drove the stock higher during the period.

  • AI Platforms and Gene Therapy Partnership New AI platforms aim to cut trial delays by up to two years, and a Medera partnership expands gene therapy reach. These initiatives position IQVIA for future growth and efficiency.

    These new strategic moves support the bullish narrative and future earnings potential.

  • Buybacks and Attractive Valuation The company executed $950M in buybacks, and the stock remains cheap at 16.2x forward earnings. Shares have rallied 42% in three months, aided by these repurchases.

    Buybacks and low valuation attracted investors and contributed to the price rally.

  • Debt Refinancing Raises Interest Costs IQVIA priced $2B in 6.375% senior notes to refinance 5% debt, adding roughly $27.5M in annual interest expense—a modest but real headwind to future profits. Also, the rally means shares are no longer inexpensive.

    This is a counterweight that could pressure future earnings and limit further upside.

Latest
▲3▼1

IQVIA's record bookings, AI launches, and cheap valuation drive the stock

  • Record bookings and raised guidance IQVIA's second-quarter results beat expectations, with adjusted earnings up 12.1% and revenue up 8.7%. Crucially, new clinical bookings jumped 19% to $3.2 billion, a record, and the company raised its full-year revenue outlook. Strong bookings signal future growth, which supports a higher stock price.

    This is the core fundamental driver: accelerating demand and raised guidance directly boost investor confidence and the stock's value.

  • AI products speed up clinical trials IQVIA launched two AI-powered platforms: Predictive Clinical Development and Life Science Models. These tools aim to cut trial delays by up to two years and improve prediction accuracy. If adopted, they could win more business and make IQVIA's services more valuable, pushing the stock up over time.

    New AI products are a key growth catalyst, showing innovation that can expand IQVIA's market and margins.

  • Cheap valuation and buybacks IQVIA trades at a forward P/E of 16.2, much lower than peers like Penumbra, and has a Value grade of B. The company also bought back $398 million of shares in Q2, reducing the share count. A low valuation plus buybacks can attract investors and lift the stock.

    Valuation and capital returns are direct price drivers, making IQVIA look attractive relative to peers.

  • Higher interest costs from new debt IQVIA priced $2 billion in senior notes at 6.375% to refinance older 5% debt. This raises annual interest expense by about $27.5 million, slightly reducing future profits. While manageable, it's a headwind that could weigh on the stock.

    This is the main counterweight: increased debt costs pressure earnings, balancing the positive drivers.

▲4

IQVIA beats Q2, raises 2026 outlook on record bookings

  • Q2 beat and raised 2026 guidance IQVIA reported Q2 revenue of $4.37 billion (up 8.7%) and earnings of $3.15 per share, beating estimates. Management raised full-year 2026 revenue and profit guidance, pushing shares up 5% after hours and nearly 14% the next day. This directly lifts the stock because future profits are now expected to be higher.

    The earnings beat and guidance raise are the core new event that moved the stock this period.

  • Record $3.15B bookings and $34.2B backlog IQVIA's R&D Solutions unit signed a record $3.15 billion in new contracts in Q2, up 19% from a year ago. Its total contracted backlog hit a record $34.2 billion, with $9.2 billion expected to convert to revenue within 12 months. This signals strong future demand and supports the stock.

    Record bookings and backlog are new, concrete evidence of future revenue growth that investors care about.

  • Medera collaboration expands gene therapy reach IQVIA announced a partnership with Medera to combine its clinical trial and commercialization network with Medera's cardiac gene therapy and human-based drug discovery platforms. This expands IQVIA's presence in cell and gene therapy, a high-growth area, and supports its long-term R&D pipeline.

    This is a new strategic partnership that broadens IQVIA's technology and service offerings.

  • Stock up 42% in three months on strong results IQVIA shares have rallied 41.5% over the past three months, far outpacing the industry and the S&P 500. The run reflects the strong bookings, raised guidance, and $950 million of share buybacks in the first half of 2026. Momentum can attract more buyers, but also means the stock is no longer cheap.

    This summarizes the market's reaction to the new fundamentals and highlights the strong momentum, while noting valuation risk.